J&J prostate cancer drug shows positive trial results before surgery

May 31, 2026 8:28 AM

Johnson & Johnson (NYSE: JNJ) announced that its Phase 3 PROTEUS study demonstrated that apalutamide combined with hormone therapy reduced ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found